Asthmatic | Difference | p-value | ||
Never-smokers | Smokers | |||
Subjects n | 39 | 36 | ||
Δ Morning PEF L·min-1 | 20.4±50.1 | 6.3±44.8 | 26.2 (2.5–50) | 0.031 |
Δ Night PEF L·min-1 | 9.1±44.1 | 14.6±46.1 | 2.3 (-21–26) | 0.84 |
Δ Pre-salbutamol FEV1 mL | 165±390 | 85±303 | 98 (-71–266) | 0.25 |
Δ Post-salbutamol FEV1 mL | 8±436 | -81±195 | 126 (-38–290) | 0.13 |
Δ Reversibility with salbutamol % | -9.3±13 | -10.5±14 | 3.0 (-2.8–6.8) | 0.25 |
Δ Daytime symptoms | -1.8±3.1 | -0.8±4.9 | -2.3 (-4– -0.4) | 0.016 |
Δ Night-time symptoms | -0.1±0.4 | -0.2±0.9 | -0.2 (-0.5–0.1) | 0.12 |
Δ Rescue medication use | -0.7±1.3 | -0.1±1.6 | -0.8 (-1.5– -0.1) | 0.029 |
Δ Asthma control score | -0.46±0.84 | -0.31±1.25 | -0.9 (-1.4– -0.4) | 0.001 |
Δ Exhaled NO ppb | -12.4±15.1 | -2.6±8.4 | 3.2 (0.1–6.4) | 0.043 |
Δ Exhaled CO ppm | 0.2±2.8 | -0.9±8.8 | -5.5 (-10– -0.7) | 0.025 |
Data are presented as mean±sd and mean (95% confidence interval), unless otherwise stated. All variables have been analysed by ANCOVA. Δ: change; PEF: peak expiratory flow; FEV1: forced expiratory volume in one second; NO: nitric oxide; CO: carbon monoxide. #: 40 mg for 2 weeks.